Feb. 17 at 4:53 PM
$CABA 🚀
$NVDA $TSLA – Remember the IPO + Follow the Rotation 🧬
Cabaletta Bio went public in October 2019 at
$11 per share. This wasn’t a hype SPAC. It was a clinical-stage biotech bringing engineered T-cell therapy into autoimmune disease — a massive addressable market.
Fast forward to today…
We’re seeing clear rotation into small caps and biotech as capital shifts out of overcrowded mega-cap trades. When money rotates, it looks for:
• Innovation
• Clinical catalysts
• Undervalued pipelines
• Tight floats
• Institutional sponsorship
CABA checks those boxes.
Institutions like T. Rowe Price still holding ~10% confirms serious sponsorship. That matters in a small cap. Float tightens. Supply shrinks. Pressure builds.
Technically,
$3 was resistance. When small caps rotate, names with real science and short interest get attention fast.
Small cap biotech doesn’t move slowly when the tide turns.
26% short 😆 
Insiders buying 
Know what you own.
